Abcellera Stock Analysis

ABCL -  USA Stock  

USD 9.74  0.03  0.31%

The big decline in price over the last few months for Abcellera Biologics could raise concerns from stakeholders as the firm it trading at a share price of 9.74 on 1,150,517 in volume. The company executives failed to add value to investors and positioning the firm supply of money to exploit market volatility in December. However, diversifying your holdings with Abcellera Biologics or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.78. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Abcellera Biologics partners.
Please continue to Trending Equities.

Abcellera Stock Analysis 

The Abcellera Biologics stock analysis report makes it easy to digest most publicly released information about Abcellera Biologics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Abcellera Stock analysis module also helps to analyze the Abcellera Biologics price relationship with some important fundamental indicators such as market cap and management efficiency.

Abcellera Stock Analysis Notes

About 30.0% of the company shares are held by company insiders. The book value of Abcellera Biologics was presently reported as 3.39. The company has Price/Earnings To Growth (PEG) ratio of 2.99. Abcellera Biologics had not issued any dividends in recent years. AbCellera Biologics Inc. develops antibody discovery platform. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada. Abcellera Biologics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 360 people. For more info on Abcellera Biologics please contact the company at 604 559 9005 or go to

Abcellera Biologics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Abcellera Biologics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Abcellera Biologics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Abcellera Biologics generated a negative expected return over the last 90 days
Abcellera Biologics has high historical volatility and very poor performance
About 30.0% of the company shares are held by company insiders

Abcellera Biologics Upcoming and Recent Events

Earnings reports are used by Abcellera Biologics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Abcellera Biologics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report4th of April 2022
Next Earnings Report12th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End4th of April 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Abcellera Largest EPS Surprises

Earnings surprises can significantly impact Abcellera Biologics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Abcellera Biologics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Abcellera Biologics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Abcellera Biologics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Abcellera Biologics specific information freely available to individual and institutional investors to make a timely investment decision.
7th of December 2021
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
3rd of December 2021
Financial Statements and Exhibits. Regulation FD Disclosure
9th of November 2021
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
4th of November 2021
Financial Statements and Exhibits. Regulation FD Disclosure
22nd of September 2021
Financial Statements and Exhibits. Other Events
15th of September 2021
Financial Statements and Exhibits. Other Events
12th of August 2021
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
13th of July 2021
Financial Statements and Exhibits. Other Events

Abcellera Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Abcellera Biologics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Abcellera Biologics backward and forwards among themselves. Abcellera Biologics' institutional investor refers to the entity that pools money to purchase Abcellera Biologics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Green Alpha Advisors LlcCommon Shares28.2 K403 K
Spire Wealth ManagementCommon SharesK29 K
Pacifica Partners IncCommon Shares2.4 K29 K
Capital World InvestorsCommon Shares19.8 M397.2 M
Allianz Asset Management GmbhCommon Shares11.9 M237.7 M
Baker Bros Advisors LpCommon Shares10.5 M209.4 M
Sb Management LtdCommon Shares9.8 M196.7 M
Jane Street Group LlcCall Options1.2 M23.5 M
Note, although Abcellera Biologics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Abcellera Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 2.73 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Abcellera Biologics's market, we take the total number of its shares issued and multiply it by Abcellera Biologics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Abcellera Profitablity

Abcellera Biologics' profitability indicators refer to fundamental financial ratios that showcase Abcellera Biologics' ability to generate income relative to its revenue or operating costs. If, let's say, Abcellera Biologics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Abcellera Biologics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Abcellera Biologics' profitability requires more research than a typical breakdown of Abcellera Biologics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 47.44 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 64.34 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.64.
Last ReportedProjected for 2022
Return on Average Assets 0.27  0.29 
Return on Average Equity 0.33  0.35 
Return on Invested Capital 2.11  2.28 
Return on Sales 0.81  0.87 

Management Efficiency

The entity has return on total asset (ROA) of 27.14 % which means that it generated profit of $27.14 on every $100 spent on asset. This is very large. Similarly, it shows return on stockholders equity (ROE) of 40.38 %, meaning that it created $40.38 on every $100 dollars invested by stockholders. Abcellera Biologics management efficiency ratios could be used to measure how well abcellera biologics manages its routine affairs as well as how well it operates its assets and liabilities. Return on Average Assets is expected to hike to 0.29 this year. Return on Average Equity is expected to hike to 0.35 this year. Abcellera Biologics Return on Average Assets are relatively stable at the moment as compared to the past year. The company's current value of Return on Average Assets is estimated at 0.29. Tangible Assets Book Value per Share is expected to hike to 6.69 this year, although the value of Goodwill and Intangible Assets will most likely fall to nearly 131.2 M.
Last ReportedProjected for 2022
Book Value per Share 6.00  6.47 
Enterprise Value over EBIT 58.50  58.16 
Enterprise Value over EBITDA 56.33  56.00 
Price to Book Value 11.60  11.53 
Tangible Assets Book Value per Share 6.20  6.69 
Enterprise Value9.6 B9.5 B
Tangible Asset Value987.7 M1.1 B

Technical Drivers

As of the 19th of January, Abcellera Biologics shows the mean deviation of 3.64, and Risk Adjusted Performance of (0.10). Abcellera Biologics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down nineteen technical drivers for Abcellera Biologics, which can be compared to its rivals. Please confirm Abcellera Biologics jensen alpha, semi variance, and the relationship between the standard deviation and value at risk to decide if Abcellera Biologics is priced correctly, providing market reflects its regular price of 9.74 per share. Given that Abcellera Biologics has jensen alpha of (0.65), we suggest you to validate Abcellera Biologics's prevailing market performance to make sure the company can sustain itself at a future point.

Abcellera Biologics Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Mid-point over period is an average of Abcellera Biologics highest and lowest values attained during the given period. View also all equity analysis or get more info about midpoint over period overlap studies indicator.

Abcellera Biologics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Abcellera Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Abcellera Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Abcellera Biologics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Montalbano John S over a month ago via Macroaxis 
Acquisition by Montalbano John S of 45532 shares of Abcellera Biologics subject to Rule 16b-3
Stimart Tryn over a month ago via Macroaxis 
Acquisition by Stimart Tryn of 270680 shares of Abcellera Biologics subject to Rule 16b-3
Lo Andrew over a month ago via Macroaxis 
Purchase by Lo Andrew of 86938 shares of Abcellera Biologics
Lecault Veronique over a month ago via Macroaxis 
Exercise or conversion by Lecault Veronique of 83333 shares of Abcellera Biologics subject to Rule 16b-3
Lecault Veronique over a month ago via Macroaxis 
Exercise or conversion by Lecault Veronique of 83333 shares of Abcellera Biologics subject to Rule 16b-3
Hansen Carl L G over a month ago via Macroaxis 
Exercise or conversion by Hansen Carl L G of 224500 shares of Abcellera Biologics subject to Rule 16b-3
Thermopylae Holdings Ltd over two months ago via Macroaxis 
Purchase by Thermopylae Holdings Ltd of 202960 shares of Abcellera Biologics
Hayden Michael R over three months ago via Macroaxis 
Exercise or conversion by Hayden Michael R of 270000 shares of Abcellera Biologics subject to Rule 16b-3
Falconer Ester over three months ago via Macroaxis 
Exercise or conversion by Falconer Ester of 875000 shares of Abcellera Biologics subject to Rule 16b-3
Hamer John over three months ago via Macroaxis 
Abcellera Biologics exotic insider transaction detected
Montalbano John S over three months ago via Macroaxis 
Abcellera Biologics exotic insider transaction detected
Dcvc Bio Lp over six months ago via Macroaxis 
Acquisition or disposition of Abcellera Biologics securities by Dcvc Bio Lp

Abcellera Biologics Predictive Daily Indicators

Abcellera Biologics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Abcellera Biologics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Abcellera Biologics Forecast Models

Abcellera Biologics time-series forecasting models is one of many Abcellera Biologics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Abcellera Biologics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Abcellera Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Abcellera Biologics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Abcellera shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Abcellera Biologics. By using and applying Abcellera Stock analysis, traders can create a robust methodology for identifying Abcellera entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin 0.84  0.91 
Gross Margin 0.90  0.89 
Profit Margin 0.59  0.64 
AbCellera Biologics Inc. develops antibody discovery platform. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada. Abcellera Biologics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 360 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Abcellera Biologics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Fund Screener Now


Fund Screener

Find actively-traded funds from around the world traded on over 30 global exchanges
All  Next Launch Module
Please continue to Trending Equities. Note that the Abcellera Biologics information on this page should be used as a complementary analysis to other Abcellera Biologics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Complementary Tools for Abcellera Stock analysis

When running Abcellera Biologics price analysis, check to measure Abcellera Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abcellera Biologics is operating at the current time. Most of Abcellera Biologics' value examination focuses on studying past and present price action to predict the probability of Abcellera Biologics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Abcellera Biologics' price. Additionally, you may evaluate how the addition of Abcellera Biologics to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Is Abcellera Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine Abcellera Biologics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.